A small sodium channel blocking factor in the cerebrospinal fluid is preferentially found in Guillain-Barré syndrome: a combined cell physiological and HPLC study.
The cerebrospinal fluid (CSF) of patients with Guillain-Barré syndrome (GBS) contains a low molecular weight factor with sodium channel blocking activity. This study investigated whether such activity also exists in the CSF of patients with other neurological diseases. Further, using high-performance liquid chromatography (HPLC) we tested whether the electrophysiological effect of the CSF is correlated with the size of the corresponding peak in the chromatograms. The existence of sodium channel blocking activity was tested in 27 native CSF samples of three groups of patients (group 1: GBS, n = 13; group 2: other inflammatory diseases, n = 8; group 3: controls, n = 6). NH15-CA2 neuroblastoma x glioma cells in the whole-cell recording configuration was used as a system for assaying the sodium channel blocking activity of CSF specimens. CSF shifted the steady-state inactivation curve of the sodium channels reversibly by -10.2 +/- 4.4 mV in group 1, -6.7 +/- 3.9 mV in group 2, and - 3.5 +/- 2.8 mV in group 3 (P < 0.01). The shift was greater in demyelinating (9.3 +/- 4.7 mV) than in nondemyelinating (5.6 +/- 3.9 mV) diseases (P < 0.04). HPLC analysis of CSFs showed a well separated peak containing the substance responsible for the electrophysiological effect at about 41 min elution time. The peak covered the molecular weight range of 600-800 Da. Sodium channel blocking activity of CSFs and areas of the corresponding peak in the chromatograms were well correlated. We conclude that sodium current inhibition by a low molecular weight factor is generally present but increased in GBS.
Weber
F
F
Department of Neurology, Military Hospital Ulm, Oberer Eselsberg 40, D-89070 Ulm, Germany.
Brinkmeier
H
H
Aulkemeyer
P
P
Wollinsky
K H
KH
Rüdel
R
R
D002555:Cerebrospinal Fluid / Q000737:chemistry / Q000502:physiology*; D002851:Chromatography, High Pressure Liquid; D003711:Demyelinating Diseases / Q000134:cerebrospinal fluid / Q000378:metabolism; D004594:Electrophysiology; D020275:Guillain-Barre Syndrome / Q000134:cerebrospinal fluid / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D008970:Molecular Weight; D009422:Nervous System Diseases / Q000134:cerebrospinal fluid / Q000378:metabolism; D009474:Neurons / Q000378:metabolism / Q000502:physiology; D026941:Sodium Channel Blockers; D014407:Tumor Cells, Cultured
D026941:Sodium Channel Blockers